- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Atopic dermatitis
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 168KB)
Dupilumab – March 2022
Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent®
Last updated
1 July 2022